DIABETES DRUGS
TODAY'S HEADLINES
FDA's approval of a new indication for empagliflozin (Jardiance) could net a pharma company more than $1 billion. Read more |
|
Two new studies on a biosimilar to trastuzumab (Herceptin) to treat HER2-positive metastatic breast cancer and HER2-positive gastric cancer demonstrated equivalency to the biologic. Read more
|
CONTINUING PHARMACY EDUCATION
This month's CE activity, "Addressing unique medication adherence issues for patients with schizophrenia," is open for pharmacists and pharmacy technicians.
The goal of this activity is to educate pharmacists and pharmacy technicians in how to best assist patients in the use of medications to treat schizophrenia.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More
|
EDITOR'S PICK
Two new diabetes drugs, both long-acting injectable insulin products, were simultaneously approved by FDA. Read more |
|
|
